New radioactive drug aims to halt bone metastases in advanced cancers
NCT ID NCT07249892
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This clinical trial tests a new drug called BPR-6023021, which is a radioactive compound designed to target bone. It is for people with advanced solid tumors that have spread to the bone and who have no other standard treatment options. The study will enroll 195 participants to evaluate the drug's safety, how it moves through the body, and whether it can slow bone tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BPR-6023021 (a radioactive drug that targets bone)
What this could lead to
If it works, this could provide a new treatment option to control bone metastases and delay disease progression in advanced solid tumors.
What could go wrong
This is an early-phase trial (Phase I/II) with only 195 participants, so safety and effectiveness are not yet proven. The drug is radioactive, which carries risks of side effects like bone marrow suppression or organ damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••